Navigation Links
CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago

Chicago, IL -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies today presented a poster abstract at the 43rd American Society of Clinical Oncology (ASCO) Annual meeting. The poster, entitled "Preliminary Results of a Phase 1 Clinical Trial of CYT-6901," announced the preliminary data of a National Cancer Institute conducted and CytImmune Sciences sponsored Phase 1 trial of CYT-6091 (Aurimune), CytImmune's lead drug compound. The Phase 1 clinical trial was designed to investigate whether: (1) Aurimune will perform identically in humans as it did in preclinical studies and companion animals and (2) the fever side effect observed in preclinical studies can be easily managed and separated from hypotension - the dose limiting side effect of the active pharmaceutical ingredient.

"This is a tremendous opportunity for CytImmune," said Dr. Lawrence Tamarkin. "Presenting preliminary Phase 1 trial results to the leading body of international oncology experts helps pave the way for nanomedicines as the next generation of targeted cancer therapies and their use in improving the biodelivery of potent, but highly toxic therapeutics. We believe CYT-6091 has the potential to become a new, versatile therapeutic which may be used to treat a broad spectrum of solid tumors."

CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer PEGylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities.

To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby av
'"/>




Page: 1 2 3

Related medicine technology :

1. CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Post Your Comments:
(Date:11/23/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...ketforPACSandEMR ,, http://www.reportlinker....ource=prnewswire&utm_medium=pr&utm_campaig...aluedatalmost$1.3billion,representinganincreaseof6...0+beds),mediumhospitals(201-499beds),communityhosp...
(Date:11/23/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...onitoringSystems-AGlobalMarketReview ,, http...-Systems---A-Global-Market-Review.html#utm_source=...wswire ,, Cardiovascularmonitoringisextreme...edtobecontinuouslymonitoredduringdiagnosticaswella...
(Date:11/23/2009)...A,India,Nov.23/PRNewswire-USNewswire/--JubilantOrg...SouthernResearchInstitutetodayannouncedajointventu...onandenablingtechnologiesintheareasofOncology,Meta...Indiaarbitragedandleveragedpartnershipthatwillacce...tsworldwide.AMemorandumofUnderstandingwassignedtod...
Breaking Medicine Technology:Reportlinker Adds U.S. Market for PACS and EMR 2Reportlinker Adds U.S. Market for PACS and EMR 3Reportlinker Adds U.S. Market for PACS and EMR 4Reportlinker Adds U.S. Market for PACS and EMR 5Reportlinker Adds U.S. Market for PACS and EMR 6Reportlinker Adds U.S. Market for PACS and EMR 7Reportlinker Adds U.S. Market for PACS and EMR 8Reportlinker Adds U.S. Market for PACS and EMR 9Reportlinker Adds U.S. Market for PACS and EMR 10Reportlinker Adds U.S. Market for PACS and EMR 11Reportlinker Adds U.S. Market for PACS and EMR 12Reportlinker Adds U.S. Market for PACS and EMR 13Reportlinker Adds Holter Monitoring Systems - A Global Market Review 2Reportlinker Adds Holter Monitoring Systems - A Global Market Review 3Reportlinker Adds Holter Monitoring Systems - A Global Market Review 4Reportlinker Adds Holter Monitoring Systems - A Global Market Review 5Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 2Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 3Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 4Anthem Blue Cross and Blue Shield Adds Affinity Health System to Provider Network 61430 1Anthem Blue Cross and Blue Shield Adds Affinity Health System to Provider Network 61430 2Anthem Blue Cross and Blue Shield Adds Affinity Health System to Provider Network 61430 3Anthem Blue Cross and Blue Shield Adds Affinity Health System to Provider Network 61430 4Anthem Blue Cross and Blue Shield Adds Affinity Health System to Provider Network 61430 5Arts Way Manufacturing Announces Contract for Modular Swine Facility for the University of Georgia 14852 1Arts Way Manufacturing Announces Contract for Modular Swine Facility for the University of Georgia 14852 2Arts Way Manufacturing Announces Contract for Modular Swine Facility for the University of Georgia 14852 3Wyle Personnel Take Part in Important Studies Aboard the International Space Station 14850 1Wyle Personnel Take Part in Important Studies Aboard the International Space Station 14850 2Wyle Personnel Take Part in Important Studies Aboard the International Space Station 14850 3
... YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex...ed in Nucleic,Acids Research by a group of researc...ty of furamidine to inhibit a key enzyme involved ...dine is the active metabolite (DB75),of Immtech,s ...dine. Of,interest is furamidine,s potential to inh...
...medical Real Estate Group Backs Construction of Fa...,(Amex: CVM ) announced today that it has entered...roup under which CEL-SCI acquires long term use of... drug Multikine(R). The,financial value of this tr...cility is located near Baltimore, Maryland. Once f...
Other Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 2CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 4
(Date:11/24/2009)... WASHINGTON,Nov.24/PRNewswire-USNewswire/--Newpeer...rly4millionAmericansinfectedwithchronichepatitisCv...ldbeawake-upcallthatCongressneedstomoveurgentlyonb...on,research,andsurveillanceefforts,the NationalVir...HRwarnsthatwithoutcongressionalaction,millionsofAm...
(Date:11/23/2009)...ent metobolomics study by researchers from Virgini...nd found that impaired peroxisomal oxidation of po...h the progression of nonalcoholic fatty liver (NAF...tudy also found significantly higher plasma monoun...h NAFL and NASH. Full findings appear in the Dece...
(Date:11/23/2009)...xpayers may be on the hook for the high cost of dr...cording to a new study led by a University of Brit...udy, published today in the Archives of Internal ...dogrel, a top-selling drug also known by the trade...rt attack or stroke. The drug was selected to stud...
(Date:11/23/2009)... AmericanCollegeofMedicalGenetics(ACMG)Encourages...tionalFamilyHistoryDay,Thanksgiving2009 ,, BET...sgivingisthesixthannualNationalFamilyHistoryDay,as...ofMedicalGenetics(ACMG)encourageseveryonetoknowthe...redthispotentiallylife-savinginformation,to"startt...
(Date:11/23/2009)... HATBORO,Pa.,Nov.23/PRNewswire-FirstCall/--InfoLog...fenterprisemobilitysolutionsforthehealthcareandcom...icePresidentofManagedServicesatSiemensHealthServic...lthcareServices. ,, (Logo: http://www.newscom.c...ePresidentofStrategicHealthcareServicesforInfoLogi...
Breaking Medicine News(10 mins):Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:Metobolomics uncovers key indicators of nonalcoholic fatty liver disease 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2Health News:'Family Health History and Genetics Privacy' is the Newest Addition to the ACMG Genetics & Your Health Video Series 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3
...on a hunger strike over quota issue at the campus ...// , called off the strike tonight, according to a...Meanwhile, the general strike by over 700-odd medi...nit) office from Chowk Bazar to district collector...
...i-hit village Nagapattinam,May 25 (pti) As part of...ty centre was inaugurated at Thennampattinam, a ts... district. Prof Dr K Wucherer,member, corpora...t foundation through Srinivasan services trust. ...
...stration chief Commissioner Lester Crawford preven...e of action on Barr Pharmaceuticals Inc.'s Plan B,...ements were contained in the transcripts released ...ing of approving the action to sell Plan B as a OT...
...ounced by the greater Southern Area Health Service...ho are unable to support// patients affected with ...vides region’s new family sensitive mental health ..., said that it was good news for families and othe...
...(RBWH), Sydney struggles with an outbreak of antib...// in three wards were found with a bacterium cal...(CRAB) on their skin. To prevent the spread, 1... Patients from both intensive care unit and the...
...lleges in West Bengal continued to be paralysed fo...eir stir against the Centre's decision to introduc... Over 2000 interns, housestaff and post grad...rotest meetings, dharnas and hunger strikes. ...
Other Medicine News:
...rm: Granular, free flowing powder EEO(-m r ): les...than or equal to 31C Remelt Point (3%): less ...r than or equal to 500 gm/cm 2 Gel Strength (5...re: less than or equal to 7% Turbidity (3%...
...g sulfate (SO 4 ) ≤ 1000 mg/kg Cation traces...; 5 mg/kg Cr ≤ 5 mg/kg Cu ≤ 5 mg/kg Fe... mg/kg Mn ≤ 5 mg/kg Na ≤ 2000 mg/kg Ni...g/kg Special grade: for molecular biology Quality ...
Agarose - BioChemika, for molecular biology, mixture of wide range and standard types 3:1
Agarose, ultra high resolution, Molecular Biology Grade
Medicine Products: